NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Danish biotech and healthcare sector declined 0.4%. Most notably, Evaxion and Genmab announced leadership changes, FluoGuide provided a business update with the expectation of multiple partnerships to be agreed in 2025, and 2cureX signed an LOI with PreComb Therapeutics AG. Furthermore, Pila Pharma initiated a rights issue of MSEK 20, while Initiator Pharma raised MSEK 48.3. Finally, Zealand Pharma got a new price target at more than twice its current stock price.
Latest news for the Danish biotech companies
Acarix AB has developed a technology to identify heart diseases. Moving forward, product sales are the main driver for the stock.
No news in the past week
Ascendis Pharma develops so-called prodrugs, which are medications that start in an inactive form and become active once inside the body. The main stock price driver going forward is the development and commercialization of its TransCon technology.
No news in the past week
Biosergen is developing BSG005 to treat serious and life-threatening fungal infections safely and with limited side effects, contrary to current drugs. The main price triggers are centered around product development and the ongoing clinical trials
No news in the past week
Cessatech develops pain treatments for children. The company is finalizing its phase 3 study for its lead candidate, and the main price driver will be the commercialization for this product.
No news in the past week
Curasight is focused on diagnosing (uTRACE) and treating cancer (uTREAT) through targeted radionuclide therapy. The benefit is treating cancer at the cellular level without harming healthy cells. The main driver of the stock moving forward is the financing of the portfolio as well as pipeline and partnership development. You can read our full investment case here (in Danish).
No news in the past week
DanCann Pharma focuses on discovering, developing, and producing medical cannabis for pain and neurological conditions. The stock price drivers are regulatory progress and sales development.
No news in the past week
Evaxion Biotech develops personalized immunotherapies and vaccines, with recent advancements in their cancer vaccine candidate EVX-01. Clinical trial outcomes and technological innovations currently drive the stock price.
Evaxion announced several changes to its executive management, where, amongst others, their CEO Christian Kanstrup is stepping down.
ExpreS2ion provides protein production technologies for vaccine development and has its own pipeline. Key stock drivers include pipeline progression and licensing agreements.
Austrian regulatory green light enables ADC combination testing and phase I site expansion for ES2B-C001, a first-in-class breast cancer immunotherapy
Fluoguide develops tumor-targeted products that make cancer visible on imaging solutions to improve cancer surgery outcomes, especially within brain and head & neck cancer surgery. The main stock driver is the clinical validation of their imaging technology and additional partnerships.
FluoGuide provided a business update with several encouraging milestones to come. The company expects to submit several applications for registration of FG001, complete pre-clinical trials, enrollment of patients in new trials as well as 1-2 new partnerships in 2025.
Genmab focuses on creating differentiated antibody therapeutics for the treatment of lymphatic leukemia and solid tumors. Genmab has developed Darzalex, with sales of nearly USD 12 billion in 2024. The stock performance is primarily driven by product sales and pipeline developments.
Genmab announced a new Chief Legal Officer.
Gubra offers preclinical contract research services and develops treatments for metabolic diseases. Key stock drivers are partnerships and progress in their internal drug pipeline.
No news in the past week
Initiator Pharma develops treatments for erectile dysfunction and neuropathic pain. The main stock catalyst is the outcome of clinical trials.
Initiator Pharma’s rights issue was completed, raising MSEK 48.3 before issuance costs.
IO Biotech is developing immune-modulating therapies for cancer, with a focus on conditions like melanoma. Stock performance is driven by clinical trial advancements.
No news in the past week
Pila Pharma is working on TRPV1 antagonists aimed at treating type 2 diabetes. Early clinical data and funding developments are key stock drivers.
The subscription period of Pila Pharma’s rights issue has started with the hope of raising MSEK 20. The subscription period runs until July 15, 2025, with a subscription price of SEK 2 per unit, corresponding to SEK 2 per share. Additionally, you will receive a warrant of series TO2.
Saniona focuses on ion channel-targeted therapies, including rare eating disorders. The main stock driver is the progression of their clinical pipeline and the approval of the weight loss drug Tesofensine in Mexico.
No news in the past week
Scandion Oncology is developing treatments to overcome chemotherapy resistance in cancer patients. The company has recently faced significant financial challenges, thus, financial stability is the main driver for the stock price.
No news in the past week
SynAct Pharma develops drugs targeting inflammatory diseases through melanocortin pathways. Clinical milestones significantly influence stock performance
SynAct Pharma announced that all members of its board and executive management have agreed to a lock-up arrangement for their shares in the company until December 31, 2025. In total, these lock-up agreements correspond to 6.9% percent of the votes and capital in SynAct Pharma.
ViroGates provides prognostic products for acute care settings to improve patient triage. Stock drivers include hospital adoption rates and revenue growth.
No news in the past week
Y-mAbs Therapeutics develops antibody-based therapies for pediatric cancers. Stock performance is driven by regulatory approvals and commercialization efforts.
No news in the past week
Zealand Pharma specializes in peptide-based treatments for metabolic and gastrointestinal diseases. The stock has seen increased awareness following the obesity hype, and advancements in its late-stage pipeline and partnerships are key stock price influencers.
Kirsty Ross-Stewart initiated their coverage of Zealand Pharma with a buy recommendation at DKK 905 per share.
2cureX offers the IndiTreat platform for individualized cancer treatment testing. The main stock driver is the adoption of their technology by hospitals and subsequent sales growth.
2cureX announced that they have signed a letter of intent (LOI) together with PreComb Therapeutics AG based in Switzerland to explore a strategic alliance that could align the scientific and commercial strengths of both companies to establish a new global benchmark in functional precision oncology.
The latest share price developments for the Danish biotech stocks
On average, the Danish biotech and healthcare stocks delivered a negative return of 0.4%. Most notably, Evaxion and Genmab announced leadership changes, FluoGuide provided a business update with the expectation of multiple partnerships to be agreed in 2025, and 2cureX signed an LOI with PreComb Therapeutics AG. Furthermore, Pila Pharma initiated a rights issue of MSEK 20, while Initiator Pharma raised MSEK 48.3. Finally, Zealand Pharma got a new price target at more than twice its current stock price.
Overview of share price development in the past week, year-to-date, and the last twelve months
DanCann Pharma does not appear on the list due to data issues.
